{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:37:33Z","timestamp":1791805053166,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21bm0404076h0001"],"award-info":[{"award-number":["21bm0404076h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K19508, JP23K18300, and JP23H04781"],"award-info":[{"award-number":["JP21K19508, JP23K18300, and JP23H04781"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04191-0","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T07:42:33Z","timestamp":1760341353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor"],"prefix":"10.1007","volume":"74","author":[{"given":"Yosuke","family":"Kogue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Okuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"4191_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Mackall CL (2019) Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med 25:1341\u20131355. https:\/\/doi.org\/10.1038\/s41591-019-0564-6","journal-title":"Nat Med"},{"key":"4191_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359:1361\u20131365. https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"key":"4191_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH (2023) CAR t therapy beyond cancer: the evolution of a living drug. Nature 619:707\u2013715. https:\/\/doi.org\/10.1038\/s41586-023-06243-w","journal-title":"Nature"},{"key":"4191_CR4","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr (2023) Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol 24:1994\u20132007. https:\/\/doi.org\/10.1038\/s41590-023-01659-y","journal-title":"Nat Immunol"},{"key":"4191_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K (2022) Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 22:557\u2013575. https:\/\/doi.org\/10.1038\/s41568-022-00491-0","journal-title":"Nat Rev Cancer"},{"key":"4191_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G et al (2018) Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32:520\u2013531. https:\/\/doi.org\/10.1038\/leu.2017.226","journal-title":"Leukemia"},{"key":"4191_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382:545\u2013553. https:\/\/doi.org\/10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"key":"4191_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R et al (2024) Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med 30:772\u2013784. https:\/\/doi.org\/10.1038\/s41591-023-02785-8","journal-title":"Nat Med"},{"key":"4191_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","volume":"130","author":"SO Ciurea","year":"2017","unstructured":"Ciurea SO, Schafer JR, Bassett R et al (2017) Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130:1857\u20131868. https:\/\/doi.org\/10.1182\/blood-2017-05-785659","journal-title":"Blood"},{"key":"4191_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjh.14570","volume":"177","author":"N Shah","year":"2017","unstructured":"Shah N, Li L, McCarty J et al (2017) Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177:457\u2013466. https:\/\/doi.org\/10.1111\/bjh.14570","journal-title":"Br J Haematol"},{"key":"4191_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/eji.201948375","volume":"50","author":"XY Zhao","year":"2020","unstructured":"Zhao XY, Jiang Q, Jiang H, Hu LJ, Zhao T, Yu XX, Huang XJ (2020) Expanded clinical-grade membrane-bound IL-21\/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur J Immunol 50:1374\u20131385. https:\/\/doi.org\/10.1002\/eji.201948375","journal-title":"Eur J Immunol"},{"key":"4191_CR12","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ, Senyukov VV, Somanchi SS et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7:e30264. https:\/\/doi.org\/10.1371\/journal.pone.0030264","journal-title":"PLoS ONE"},{"key":"4191_CR13","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.omtm.2024.101374","volume":"32","author":"T Wibowo","year":"2024","unstructured":"Wibowo T, Kogue Y, Ikeda S et al (2024) CAR-NK cells derived from cord blood originate mainly from CD56(-)CD7(+)CD34(-)HLA-DR(-)Lin(-) NK progenitor cells. Mol Ther 32:101374. https:\/\/doi.org\/10.1016\/j.omtm.2024.101374","journal-title":"Mol Ther"},{"key":"4191_CR14","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1158\/0008-5472.can-10-3843","volume":"71","author":"H Singh","year":"2011","unstructured":"Singh H, Figliola MJ, Dawson MJ et al (2011) Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71:3516\u20133527. https:\/\/doi.org\/10.1158\/0008-5472.can-10-3843","journal-title":"Cancer Res"},{"key":"4191_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376\u2013383. https:\/\/doi.org\/10.1182\/blood-2004-12-4797","journal-title":"Blood"},{"key":"4191_CR16","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/j.1460-2075.1994.tb06576.x","volume":"13","author":"JG Giri","year":"1994","unstructured":"Giri JG, Ahdieh M, Eisenman J et al (1994) Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13:2822\u20132830. https:\/\/doi.org\/10.1002\/j.1460-2075.1994.tb06576.x","journal-title":"EMBO J"},{"key":"4191_CR17","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2326-6066.Cir-23-0151","volume":"11","author":"C Zhang","year":"2023","unstructured":"Zhang C, Kadu S, Xiao Y et al (2023) Sequential exposure to IL21 and IL15 during human natural killer cell expansion optimizes yield and function. Cancer Immunol Res 11:1524\u20131537. https:\/\/doi.org\/10.1158\/2326-6066.Cir-23-0151","journal-title":"Cancer Immunol Res"},{"key":"4191_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1084\/jem.20082013","volume":"206","author":"ND Huntington","year":"2009","unstructured":"Huntington ND, Legrand N, Alves NL et al (2009) IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206:25\u201334. https:\/\/doi.org\/10.1084\/jem.20082013","journal-title":"J Exp Med"},{"key":"4191_CR19","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.V83.9.2594.2594","volume":"83","author":"JS Miller","year":"1994","unstructured":"Miller JS, Alley KA, McGlave P (1994) Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood 83:2594\u20132601","journal-title":"Blood"},{"key":"4191_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186890","author":"MA Villalona-Calero","year":"2025","unstructured":"Villalona-Calero MA, Tian L, Li X et al (2025) Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.186890","journal-title":"JCI Insight"},{"key":"4191_CR21","doi-asserted-by":"publisher","first-page":"1213161","DOI":"10.3389\/fimmu.2023.1213161","volume":"14","author":"Y Mu","year":"2023","unstructured":"Mu Y, Tong J, Wang Y, Yang Y, Wu X (2023) Case report: cord blood-derived natural killer cells as new potential immunotherapy drug for solid tumor: a case study for endometrial cancer. Front Immunol 14:1213161. https:\/\/doi.org\/10.3389\/fimmu.2023.1213161","journal-title":"Front Immunol"},{"key":"4191_CR22","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1158\/1078-0432.Ccr-18-3183","volume":"25","author":"RA Burga","year":"2019","unstructured":"Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CRY, Bollard CM (2019) Engineering the TGF\u03b2 receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for Neuroblastoma. Clin Cancer Res 25:4400\u20134412. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3183","journal-title":"Clin Cancer Res"},{"key":"4191_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jcyt.2020.05.001","volume":"22","author":"SN Damodharan","year":"2020","unstructured":"Damodharan SN, Walker KL, Forsberg MH, McDowell KA, Bouchlaka MN, Drier DA, Sondel PM, DeSantes KB, Capitini CM (2020) Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. Cytotherapy 22:450\u2013457. https:\/\/doi.org\/10.1016\/j.jcyt.2020.05.001","journal-title":"Cytotherapy"},{"key":"4191_CR24","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1038\/s41467-024-47574-0","volume":"15","author":"A Berjis","year":"2024","unstructured":"Berjis A, Muthumani D, Aguilar OA et al (2024) Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nat Commun 15:3937. https:\/\/doi.org\/10.1038\/s41467-024-47574-0","journal-title":"Nat Commun"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04191-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T17:20:11Z","timestamp":1763054411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04191-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4191"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04191-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NH has applied for a Japanese patent entitled \u201cNK progenitor cells and method of producing NK cells using the progenitor cells\u201d through the Osaka University Office for University\u2013Industry Collaboration. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"338"}}